Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.

Tallini, Giovanni; Ghossein, Ronald; Emanuel, Janet Rettig; Gill, James J.; Kinder, Barbara K.; Dimich, Alexandra; Costa, José; Robbins, Richard J.; Burrow, Gerard N.; Rosaí, Juan

doi:10.1200/jco.1998.16.3.1158

Cited by 80 publications

(62 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This confirms the findings of Tallini et al (1998), who, when studying 10 non-thyroid malignant human cell lines and 11 control subjects (including one patient who had had a total laringectomy for squamous cell carcinoma with a complete thyroidectomy), found no detectable expression of Tg-mRNA after 30 cycles of PCR, but found detectable Tg-mRNA expression in all samples after 40 cycles of PCR.…”

Section: Illegitimate Transcription Of Tg-mrnasupporting

confidence: 86%

“…Thyroglobulin mRNA detection certainly does not turn out to be specific for the presence of metastatic thyroid cancer: Tg-mRNA is detected in peripheral blood samples of patients with benign thyroid disorders and even in samples from healthy subjects (Ringel et al, 1998;Tallini et al, 1998;Takano et al, 2001;Savagner et al, 2002;Elisei et al, 2004). This suggests that Tg-mRNAproducing cells are present in blood even in patients without thyroid cancer, which could be attributed to illegitimate transcription of Tg-mRNA, or could mean that cell shedding is a physiologic rather than pathologic process, taking place even in normal thyroids.…”

Section: Discussionmentioning

confidence: 99%

“…Their results however showed no benefit from these measurements: NIS-mRNA detection was inferior to Tg-mRNA detection. Tallini et al (1998) in their study correlated the detection of thyroid peroxidase (TPO) mRNA and Tg-mRNA. Thyroid peroxidase mRNA was detected in the same samples of peripheral blood as Tg-mRNA and was not found in samples in which TgmRNA was lacking.…”

Section: Alternatives To Tg-mrnamentioning

confidence: 99%

See 2 more Smart Citations

Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?

et al. 2004

View full text Add to dashboard Cite

To investigate the usefulness of thyroglobulin mRNA (Tg-mRNA) detection in peripheral blood in the follow-up of papillary and follicular (differentiated) thyroid cancer, a literature study was performed. Both evidence for and evidence against the usefulness of Tg-mRNA detection were found. Also, evidence for the expression of Tg-mRNA in cells other than normal or neoplastic thyroid follicular cells was found. It is concluded that currently Tg-mRNA detection is not a useful tool in the follow-up of differentiated thyroid carcinoma, but that the concept of using RT -PCR measurements during follow-up still warrants further research.

show abstract

Section: Illegitimate Transcription Of Tg-mrnasupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Section: Alternatives To Tg-mrnamentioning

confidence: 99%

See 1 more Smart Citation

Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Especially in prostate cancer, detection of circulating tumour cells could be shown to precede the detection of secondary disease by serum markers determined by immunoassays (Ghossein et al, 1995). To date, only three studies have been published, which have explored blood-borne thyroglobulin mRNA as a potential tumour marker in thyroid cancer (Ditkoff et al, 1996;Tallini et al, 1998;Ringel et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

“…RT-PCR is also discussed as a new diagnostic tool with increasing popularity for the clinical monitoring of thyroid cancer patients (Haber, 1998). Controversial results were published by several groups during the last years and no standardized protocol is established to date (Ditkoff et al, 1996;Tallini et al, 1998;Ringel et al, 1998). To further define the applicability and value of this method we amplified thyroglobulin (TG) mRNA transcripts from peripheral blood samples of 150 patients diagnosed with thyroid cancer, 85 patients with non-malignant thyroid disease and 50 control subjects without evidence or history of thyroid disease.…”

mentioning

confidence: 99%

True

et al. 2000

View full text Add to dashboard Cite

SummaryThe sensitive detection of circulating tumour cells in patients with differentiated thyroid cancer may precede the detection of relapse by other diagnostic studies -such as serum thyroglobulin -and thus may have important therapeutic and prognostic implications. We performed reverse transcription-polymerase chain reaction (RT-PCR) on blood samples from patients diagnosed with thyroid disease using two different RT-PCR sensitivities. Additionally, tissue specificity of TG mRNA-expression was determined using RNA extracts from 27 different human tissues. The lower limit of detection was 50-100 TG mRNA producing cells/ml blood using a 'normal' RT-PCR sensitivity and 10-20 cells/ml blood using a 'high' sensitivity. With the normal sensitivity TG mRNA was detected in 9/13 patients with thyroid cancer and metastasis, 63/137 patients with a history of thyroid cancer and no metastasis, 21/85 with non-malignant thyroid disease and 9/50 controls. With the high sensitivity TG mRNA was detected in 11/13 patients with thyroid cancer and metastasis, 111/137 patients with a history of thyroid cancer and no metastasis, 61/85 with non-malignant thyroid disease and 41/50 controls. Interestingly, using the normal RT-PCR sensitivity TG mRNA transcripts are specific for thyroid tissue and detectable in the peripheral blood of controls and patients with thyroid disease, which correlates with a diagnosis of metastasized thyroid cancer. However, with a high RT-PCR sensitivity, TG mRNA expression was found not to be specific for thyroid tissue and was not correlated with a diagnosis of thyroid cancer in patients. As a consequence, to date TG mRNA detected by RT-PCR in the peripheral blood cannot be recommended as a tumour marker superior to TG serum-level.

show abstract

Prospective multicenter study of thyroid carcinoma treatment

Sherman

Brierley

Sperling

et al. 1998

Cancer

352

View full text Add to dashboard Cite

BACKGROUND A novel prognostic staging classification encompassing all forms of thyroid carcinoma was created for the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) Registry, with the goal of prospective validation and comparison with other available staging classifications. METHODS Patient information was recorded prospectively from 14 institutions. Clinicopathologic staging was based on patient age at diagnosis, tumor histology, tumor size, intrathyroidal multifocality, extraglandular invasion, metastases, and tumor differentiation. RESULTS Between 1987 and 1995, 1607 patients were registered. Approximately 43% of patients were classified as NTCTCS Stage I, 24% Stage II, 24% Stage III, and 9% Stage IV. Patients with follicular carcinoma were more likely to have "high risk" Stage III or IV disease than those with papillary carcinoma. Of 1562 patients for whom censored follow‐up was available (median follow‐up, 40 months), 78 died of thyroid carcinoma or complications of its treatment. Five‐year product‐limit patient disease specific survival was 99.8% for Stage I, 100% for Stage II, 91.9% for Stage III, and 48.9% for Stage IV (P < 0.0001). The frequency of remaining disease free also declined significantly with increasing stage (94.3% for Stage I, 93.1% for Stage II, 77.8% for Stage III, and 24.6% for Stage IV). The same patients also were staged applying six previously published classifications as appropriate for their tumor type. The predictive value of the NTCTCS Registry staging classification consistently was among the highest for disease specific mortality and for remaining disease free, regardless of the tumor type. Conclusions The NTCTCS Registry staging classification provides a prospectively validated scheme for predicting short term prognosis for patients with thyroid carcinoma. [See editorial counterpoint on pages 844‐7 and reply to counterpoint on pages 848‐50, this issue.] Cancer 1998;83:1012‐1021. © 1998 American Cancer Society.

show abstract

Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.

Abstract: TG, TPO, and RET/PTC1 mRNA are detectable in the peripheral blood of patients with thyroid disease, which correlates with a diagnosis of carcinoma.

Cited by 80 publications

References 33 publications

Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?

Detection of circulating Tg-mRNA in the follow-up of papillary and follicular thyroid cancer: how useful is it?

True

Prospective multicenter study of thyroid carcinoma treatment

Contact Info

Product

Resources

About